Agile Therapeutics, Inc. (AGRX)
OTCMKTS: AGRX · Delayed Price · USD
0.380
+0.010 (2.70%)
Apr 19, 2024, 3:44 PM EDT - Market closed
Agile Therapeutics Stock Forecast
AGRX's stock price has decreased by -94.3% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Agile Therapeutics stock has a target of 12, which predicts an increase of 3,057.89% from the current stock price of 0.38.
Analyst Consensus: Buy
* Price targets were last updated on Jun 26, 2023.
Analyst Ratings
The average analyst rating for AGRX stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 18, 2024 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +1,215.79% | Sep 22, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +3,057.89% | Jun 26, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +3,057.89% | Jun 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $250 → $150 | Strong Buy | Maintains | $250 → $150 | +39,373.68% | Dec 30, 2022 |
Financial Forecast
Revenue This Year
37.58M
from 19.59M
Increased by 91.78%
Revenue Next Year
51.95M
from 37.58M
Increased by 38.26%
EPS This Year
0.80
from -0.01
EPS Next Year
1.12
from 0.80
Increased by 41.03%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 38.7M | 53.5M | 69.6M | 131.6M | 168.5M |
| Avg | 37.6M | 52.0M | 67.6M | 112.1M | 163.7M |
| Low | 36.1M | 49.9M | 65.0M | 92.6M | 157.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 97.4% | 42.3% | 34.0% | 94.6% | 50.3% |
| Avg | 91.8% | 38.3% | 30.2% | 65.8% | 46.0% |
| Low | 84.3% | 32.8% | 25.0% | 36.9% | 40.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 0.82 | 1.16 | 2.07 | 2.66 |
| Avg | 0.80 | 1.12 | 2.01 | 2.58 |
| Low | 0.76 | 1.08 | 1.93 | 2.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 45.2% | 84.4% | 32.2% |
| Avg | - | 41.0% | 79.1% | 28.4% |
| Low | - | 35.5% | 72.1% | 23.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.